HUTCHMED (China) Ltd
00013
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
Earnings margins to improve for mining specialist
Premium products drive margins yet shares fully valued.
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,200.30 | 12.40 | -0.13% |
| CAC 40 | 8,278.77 | 7.63 | -0.09% |
| DAX 40 | 26,046.40 | 43.08 | 0.17% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,831.09 | 0.43 | -0.00% |
| HKSE | 25,537.18 | 113.69 | -0.44% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 66,464.85 | 1,443.91 | 2.22% |
| NZX 50 Index | 13,932.52 | 41.66 | -0.30% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 9,009.90 | 13.50 | -0.15% |
| SSE Composite Index | 3,940.98 | 10.87 | 0.28% |